Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid(Queen Mary University of London), Hope S. Rugo(UCSF Helen Diller Family Comprehensive Cancer Center), Sylvia Adams(NYU Langone Health), Andreas Schneeweiß(German Cancer Research Center), Carlos H. Barrios(Pontifícia Universidade Católica do Rio Grande do Sul), Hiroji Iwata(Aichi Cancer Center), Véronique Dièras(Centre Eugène Marquis), Volkmar Henschel(Roche (Switzerland)), Luciana Molinero, Jane Yuet Ching Hui, Vidya Maiya, Amreen Husain(Roche (Switzerland)), Eric P. Winer(Dana-Farber Cancer Institute), Sherene Loi(Peter MacCallum Cancer Centre), Leisha A. Emens(University of Pittsburgh Medical Center)
Cited by 1,189
Abstract
Related Papers
No related papers found
Powered by citation graph analysis